Start Date
May 31, 2023
Primary Completion Date
August 31, 2023
Study Completion Date
January 31, 2024
80 mg RPH-104
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Placebo
Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Penn State Health Hersey Medical Center, Hershey
Mayo Clinic, Rochester
National Jewish Health, Denver
Oregon Health & Science University, Portland
Collaborators (1)
Worldwide Clinical Trials
OTHER
R-Pharm Overseas, Inc.
INDUSTRY